Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Leukemia, Myeloid, Acute × Pioglitazone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4 Polycystic Ovary Syndrome 2 Leukoplakia, Oral 2 Carcinoma, Non-Small-Cell Lung 2 Skin Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Lung Neoplasms 1 Liposarcoma, Myxoid 1 Liposarcoma 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Acute 1 Insulin Resistance 1 Head and Neck Neoplasms 1 Carotid Intimal Medial Thickness 1 1 Carcinoma, Squamous Cell 1 Breast Neoplasms 1

Interventions

Cytarabine 177 Azacitidine 128 Cyclophosphamide 121 fludarabine phosphate 95 fludarabine 84 Busulfan 84 venetoclax 82 Mycophenolic Acid 72 Whole-Body Irradiation 68 Peripheral Blood Stem Cell Transplantation 66 Tacrolimus 63 Decitabine 56 Filgrastim 50 Melphalan 46 Idarubicin 46 Cyclosporine 46 Granulocyte Colony-Stimulating Factor 44 Daunorubicin 44 Methotrexate 42 Antilymphocyte Serum 38 Etoposide 37 Clofarabine 36 Gemtuzumab 32 Mitoxantrone 30 Thiotepa 28 Stem Cell Transplantation 28 CPX-351 26 thymoglobulin 23 Radiotherapy 23 Injections 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02942758 2024-05-08

AML-ViVA

University Hospital Regensburg

Phase 2 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡